Fc gamma RIII / CD16

Fc gamma RIII / CD16 Molekülinformation

Englischer Name	Low affinity immunoglobulin gamma Fc region receptor III-A	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	14	Target-Alias	IGFR3，FCG3，Fc Fragment Of IgG， Low Affinity IIIa， Receptor For (CD16)，Fc Fragment Of IgG， Low Affinity III， Receptor For (CD16)，Immunoglobulin G Fc Receptor III，Fc-Gamma Receptor III-2 (CD 16)，Neutrophil-Specific Antigen NA，Fc-Gamma Receptor IIIb (CD16)，Fc Gamma Receptor III-A，Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment，IgG Fc receptor III-2，Low affinity immunoglobulin gamma Fc region receptor III-A，FCGR3，CD16A，Fc-gamma RIII-alpha，FCGR3A，Fc Fragment Of IgG Receptor IIIa，Fc Fragment Of IgG， Low Affinity IIIa， Receptor (CD16a)，CD16a Antigen，Fc Gamma Receptor IIIa，Fc-Gamma RIIIa，Fc-Gamma RIII，FcgammaRIIIA，FCGRIII，FcRIIIa，FCR-10，FCRIII，IMD20，CD16
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Low affinity immunoglobulin gamma Fc region receptor III-A
Target-Alias	IGFR3，FCG3，Fc Fragment Of IgG， Low Affinity IIIa， Receptor For (CD16)，Fc Fragment Of IgG， Low Affinity III， Receptor For (CD16)，Immunoglobulin G Fc Receptor III，Fc-Gamma Receptor III-2 (CD 16)，Neutrophil-Specific Antigen NA，Fc-Gamma Receptor IIIb (CD16)，Fc Gamma Receptor III-A，Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment，IgG Fc receptor III-2，Low affinity immunoglobulin gamma Fc region receptor III-A，FCGR3，CD16A，Fc-gamma RIII-alpha，FCGR3A，Fc Fragment Of IgG Receptor IIIa，Fc Fragment Of IgG， Low Affinity IIIa， Receptor (CD16a)，CD16a Antigen，Fc Gamma Receptor IIIa，Fc-Gamma RIIIa，Fc-Gamma RIII，FcgammaRIIIA，FCGRIII，FcRIIIa，FCR-10，FCRIII，IMD20，CD16
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	14
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Fc gamma RIII / CD16 Produktliste

Attribut
Protein (5)
Produktbibliothek
Online (5)
Spezies
Mouse (2)Cynomolgus (2)Rhesus macaque (1)
Etikett
His Tag (3)His Tag & Avi Tag (2)
Marker
Unconjugated (3)Biotin-labeled (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT CDA-M52H8	Mouse	HEK293	Mouse Fc gamma RIII / CD16 Protein, His Tag (SPR & MALS verified)	In den Warenkorb legen
HOT FC6-C52H9	Cynomolgus	HEK293	Cynomolgus Fc gamma RIII / CD16 Protein, His Tag (MALS & BLI verified)	In den Warenkorb legen
HOT FC6-C82E0	Cynomolgus	HEK293	Biotinylated Cynomolgus Fc gamma RIII / CD16 Protein, His,Avitag™ (MALS & BLI verified)	In den Warenkorb legen
FC6-M82E0	Mouse	HEK293	Biotinylated Mouse Fc gamma RIII / CD16 Protein, His,Avitag™ (MALS & SPR verified)	In den Warenkorb legen
FC6-R52H6	Rhesus macaque	HEK293	Rhesus macaque Fc gamma RIII / CD16 Protein, His Tag (SPR & MALS verified)	In den Warenkorb legen

Gesamtmenge5

Fc gamma RIII / CD16 Molekülhintergrund

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Fc gamma RIII / CD16 Molekülalias

FCGR3

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Acimtamig	AFM-13	Phase 2 Clinical	The University Of Texas MD Anderson Cancer Center	Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mycosis Fungoides	Details
IPH-6501	IPH-6501; IPH-65	Phase 2 Clinical	Innate Pharma SA	Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms	Details
FT-538	FT-538	Phase 2 Clinical	Fate Therapeutics Inc	Coronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; HIV Infections; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Respiratory Distress Syndrome, Adult; Solid tumours	Details
GMA-161	GMA-161	Phase 1 Clinical	Macrogenics Inc, Sanofi	Purpura, Thrombocytopenic, Idiopathic	Details
GTB-5550	GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™	Phase 1 Clinical	University Of Minnesota	Solid tumours	Details
FT-576	FT-576	Phase 1 Clinical	Fate Therapeutics Inc, University Of Minnesota	Bone Marrow Neoplasms; Multiple Myeloma	Details
AFM-28	AFM-28	Phase 1 Clinical	Affimed	Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms	Details
Donor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital)		Phase 1 Clinical	Pla General Hospital	Leukemia, Myeloid, Acute	Details
GTB-3650	GTB-3650; GTB-360; OXS-3350; OXS-C3550	Phase 1 Clinical	Masonic Cancer Center, University Of Minnesota	Bone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	Details
BGB-B3227	BGB-B3227	Phase 1 Clinical	BeOne Medicines (Beijing) Co Ltd	Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours	Details
SM-3321	SM-3321; SM3321	Phase 1 Clinical	Zhuhai StarMab BioMed Technology Ltd	Leukemia, Myeloid, Acute; Neoplasms	Details
FT-596	FT-596	Phase 1 Clinical	Fate Therapeutics Inc	Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin	Details
SAR-443579	SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101	Phase 1 Clinical	Sanofi	Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Diseases; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma	Details
FT-516	FT-516	Phase 1 Clinical	Fate Therapeutics Inc, University Of Minnesota	Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours	Details